IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2)‎ Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Abstract EN

Total serum IgG level is a surrogate marker of hepatitis C (HC) severity.

Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products.

The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in ELISA using fourteen synthetic glycans present in microbes and adhesins to evaluate the association of Abs with clinical parameters and the efficacy of antiviral treatment.

The anti-GlcNAcβ IgG level was significantly higher in patients with fibrosis (P=0.021) and severe portal inflammation (P<0.001) regardless of other clinical parameters.

The ROC curve analysis showed sensitivity of 0.59, specificity of 0.84, and AUC of 0.71 in discriminating F0 from F1–4 (HCV genotype-1b-infected patients).

The level of anti-GA2 Abs before Peg-IFN/RBV treatment was significantly higher in nonsustained viral response (non-SVR) to treatment than in SVR (P=0.033).

ROC analysis showed sensitivity of 0.62, specificity of 0.70, and AUC of 64.

Correlations of AG Abs to clinical parameters were found.

The quantification of anti-GlcNAcβ Abs deserves attention in assessment of the hepatic damage while anti-GA2 Abs may be a sign of immune response related to the antiviral treatment.